Articles tagged with Breast Cancer
A new breast cancer treatment, trastuzumab emtansine (T-DM1), has shown significant improvements over standard therapy in keeping advanced tumors from progressing, with fewer and less harsh side effects.
Researchers have identified androgen receptors as a key target for treating breast cancer, leading to the development of enzalutamide as a potential new therapy. The study suggests that blocking these receptors can inhibit cancer growth, offering new hope for patients with hormone-dependent breast cancers.
Researchers identified a genetic marker, microRNA, that differs in expression between African American and Caucasian women with breast cancer. The study found that African American patients overexpressed only six microRNAs, while Caucasian patients expressed 20 microRNAs, suggesting potential connections to treatment outcomes.
A study found that combining lapatinib and pazopanib did not improve outcomes for patients with inflammatory breast cancer, despite increased side effects. Lapatinib was shown to be an effective treatment option for women with this disease.
The US Food and Drug Administration (FDA) is issuing recommendations for breast cancer trials that would substantially accelerate patient access to new medications. The new regulatory guidelines are based in part on groundbreaking, national breast cancer research led by UCSF.
The global cancer burden is projected to rise by over 75% by 2030, driven by demographic changes and Westernized lifestyle factors. Countries with low Human Development Index (HDI) are expected to experience a significant surge in cancer cases, particularly those associated with infection.
The CNRCS has awarded three students for their work on prostate cancer, including Jayantha Tennakoon, who aims to identify molecules that provoke cancer cell growth. Undergraduate Hannah Do is maintaining a drug library to isolate new therapeutic targets for advanced prostate cancer. Eylem Aydogdu became the first Ph.D. graduate at the...
Researchers found that Skp2 E3 ligase promotes Herceptin resistance in breast cancer by activating the Akt kinase, which also regulates glucose metabolism. The study suggests that blocking Skp2 could inhibit glycolysis and provide a new approach to cancer treatment.
A study by Duke University Medical Center found that breast cancer patients have significantly impaired cardio-pulmonary function that can persist for years after treatment. Higher cardio fitness levels were linked to longer median survival among women with advanced breast cancer, suggesting exercise may be a useful intervention.
A new study shows that Breast MRI provides an indication of a breast tumor's response to pre-surgical chemotherapy significantly earlier than possible through clinical examination. MRI size measurements were superior to clinical examination at all time points, predicting both complete tumor response and residual cancer burden.
A new clinical trial is testing a combination of fulvestrant and ganetespib, an HSP90 inhibitor, to treat recurrent or metastatic estrogen receptor-positive breast cancer. The goal is to make tumor cells more susceptible to hormonal therapies.
Researchers have identified a new genetic signature associated with basal-like breast cancer, which is more prevalent in African Americans. The discovery suggests that combination therapy targeting multiple pathways could be an effective treatment strategy for this aggressive subtype.
A decade after the Women's Health Initiative stopped a widely used hormone therapy, experts have reassessed its benefits and risks. The new research supports the use of hormone therapy near menopause to alleviate symptoms and reduce the risk of heart disease and fractures for most women.
Researchers discovered a novel mechanism regulating breast cancer bone metastases and found that heparin-like compounds can inhibit bone destruction and tumor growth in bone. A promising heparin-like compound has reduced anticoagulant activity, improving its applicability as a potential cancer therapeutic agent.
A team of scientists has developed a new strategy to reactivate genes that cause cancer tumors to shrink and die. The researchers found that inhibiting the PAD4 enzyme can effectively target unhealthy, cancerous tissue without damaging healthy tissues.
A randomized clinical trial found that moderate weight loss can significantly reduce levels of circulating estrogens associated with an increased risk of breast cancer. The study, published by Fred Hutchinson Cancer Research Center, showed that losing just 5% of one's total body weight had a beneficial impact on hormone levels.
Researchers from NUS have discovered how a drug-lead compound named BPTES can deprive cancer cells of energy and stop them from growing into a tumour. Building on these findings, they also derived positive results for a novel dual-drug treatment regime that kills kidney and breast cancer cells more effectively.
A new study published in Breast Cancer Research found that panobinostat selectively targets and destroys triple negative breast cancer cells. The HDAC inhibitor also reduces tumor growth in mice and partially reverses the morphological changes in cells to a more epithelial type.
A team of researchers at the Wellcome Trust Sanger Institute sequenced the genomes of 21 breast cancers, revealing new mutation processes that drive their development. The study found that these mutations accumulate over time, creating a complex landscape of genetic changes in the cancer cells.
A hybrid vaccine has demonstrated a 43% reduction in risk of recurrence, with an estimated rate of 10.3% compared to 18% in control group, in patients with varying levels of HER2 expression.
A study published in Science Translational Medicine found that daclizumab improved the survival of breast cancer patients taking a cancer vaccine by 30%, compared to those not taking daclizumab. The drug depletes regulatory T cells, allowing immune cells to fight tumors more effectively.
Researchers will investigate Cu-64, a biomolecule that selectively seeks out a prostate tumor biomarker, to stage prostate cancers and detect recurrent disease accurately. The new technique involves PET scans and could significantly reduce the number of confirmation biopsies.
Researchers investigated whether preoperative imaging differed between black and white women with breast cancer. They found no disparity in the use of imaging, contrary to some earlier studies. However, they did note that women from more educated areas were more likely to receive certain types of imaging.
Researchers identify nine new genes that drive breast cancer development, highlighting the genetic diversity of the disease. The study provides insights into the consequences of this diversity and its implications for treatment.
A collaborative study is exploring the proteome of triple negative breast cancers to identify new drug therapies and diagnostic tools. The researchers aim to understand how cancer cells operate and find proteins that could suggest treatment options.
Researchers at the University of Missouri discovered that apigenin slows breast cancer cell growth by inducing cell death, inhibiting proliferation, and reducing gene expression. Apigenin-treated mice showed smaller tumors and restricted nutrient flow to cancer cells.
Researchers identified a cell surface protein ganglioside GD2 that flags breast cancer stem cells as potent tumor-generating cells. A small molecule drug triptolide inhibits GD3 synthase, essential to GD2 production, and stymies cancer growth in preclinical tests.
Research reveals a link between Glyoxylase 1 and increased anxiety in mice, with implications for potential therapeutic targets. Additionally, studies provide hope for new treatments for the rare disease Beare-Stevens syndrome and graft versus host disease.
A multicenter study found that the Breast Imaging and Reporting Data Systems (BI-RADS) terminology used by radiologists is useful in predicting malignancy in breast lesions detected with MRI. Features such as irregular shape, spiculated margins, and marked enhancement are most predictive of cancer.
A cancer vaccine targeting MUC1 glycoprotein significantly increased survival when combined with the drug letrozole in mice. The findings suggest a promising new approach to combating cancer using immunotherapy.
A new technique called Deep Inspiration Breath Hold (DIBH) helps deliver the correct dose to the right place, sparing healthy tissue. The study found that treating patients during DIBH reduced the heart mean dose by 68% and lung radiation by 20-30%, offering a clinical benefit for breast cancer patients.
A randomized trial found that highly targeted irradiation had equally good results as whole breast radiotherapy in early stage cancer, with a lower risk of adverse effects. The treatment reduced the rate of local recurrence by 0.8% and improved cosmetic outcomes by 18%, making it a potential game-changer for breast cancer patients.
Researchers developed gene expression signatures to predict breast cancer patient responses to chemotherapy. The signatures, based on TOP2A and β-tubulin, accurately predicted complete response rates and combined indices improved accuracy.
A study of 163 patients with cervical cancer found that 3D image-guided adaptive brachytherapy (IGABT) achieved high rates of tumor control and low side effects, making hysterectomies unnecessary for most women. The technique was effective in controlling the return and spread of the disease, and overall survival was 84% after three years.
A recent study published in the Journal of the National Cancer Institute found that physical activity is associated with reduced mortality in breast and colon cancer patients. The research suggests that exercise may provide benefits such as improved insulin levels, reduced inflammation, and enhanced immunity for cancer survivors.
A new Stanford study reveals that the cells sloughed off from a cancerous tumor into the bloodstream are genetically diverse and may require different treatments. The research found that these cells can express genes that predict their response to therapy, highlighting the need for personalized treatment approaches.
Research reveals that commonly occurring large chromosomal deletions contain areas with multiple functionally linked genes whose loss confers a survival advantage on tumors. The study validated the presence of these linked genes in mouse models of human liver cancer and demonstrated their cooperative action.
Researchers developed a new imaging device that uses photoacoustics to detect breast tumors, revealing high-contrast images of malignant tissue. The technology combines light-based system with ultrasound, providing superior targeting ability and potentially clinically useful for making breast cancer diagnoses.
A new study found that preoperative MRI exams are equally effective in detecting additional malignancies and high-risk lesions in both dense and non-dense breasts. The study suggests that breast density should not influence the decision to perform a preoperative MRI.
Heidelberg University Hospital's Breast Center reports excellent treatment results for breast cancer patients in Germany. Eighty-six percent of patients survived the first five years after onset of treatment and 80% remained disease-free during this period.
Research reveals breast cancer in young women is often diagnosed at an advanced stage, with a significantly higher risk of relapse independent of other factors. Genomic analysis identified age-related biological processes and potential targets for treatment, including the phosphoinositide 3-kinase molecular pathway and RANKL.
A new study conducted at Elizabeth Wende Breast Care in Rochester, NY found that women aged 40-49 with no family history of breast cancer are still at a high risk of developing invasive disease. The study included 211 women who underwent screening mammography and found that 64% had invasive disease.
Researchers identified a group of patients with high immune response gene expression who are more likely to have their tumors completely eradicated by pre-operative chemotherapy. Patients with HER2-positive and ER-negative/HER2-negative subtypes showed better treatment outcomes.
A new study reveals that automated breast ultrasound can detect additional clinically significant breast cancers missed by mammography, in just three minutes of physician time. This technology is a game-changer for women with dense breasts, who are at higher risk of missing cancer diagnoses.
Researchers have found that measuring progesterone receptor expression can improve hormone-receptor-positive breast cancer management. The study identifies a subpopulation of patients with high survival rates when treated with endocrine therapy alone, and could lead to a more personalized medicine approach in breast cancer.
Researchers have made significant breakthroughs in understanding the biological differences between individual breast cancers, highlighting the importance of biomarkers in identifying new targets for therapy. Studies also explored the mechanisms behind endocrine resistance and proposed a new approach to predicting response to treatment.
A new study found that women with benign breast biopsies do not require close surveillance at six or twelve months, and may not need follow-up care at all. The study suggests an annual mammogram could replace the need for follow-up examinations.
Scientists at UCSF used a pioneering imaging technique to study the interaction between breast cancer and the immune system in mice. They found that activated immune cells are headed off at the pass by healthy cells forming a 'thin red line' around tumors.
A study from the University of Texas M.D. Anderson Cancer Center found that Accelerated Partial Breast Irradiation (APBI) is associated with a higher risk of later mastectomy, increased radiation-related toxicities and post-operative complications compared to traditional whole breast irradiation.
Researchers estimate that screening mammography for women aged 40-49 with a twofold increased risk level of breast cancer has similar benefits and harms as average-risk women who start biennial screening at age 50. Factors such as family history and dense breasts increase risk by twofold.
Researchers found that most African-American breast cancer survivors were satisfied with their treatment but lacked access to critical information about treatment options, support services, and clinical trials. Only 62% of women received information about support services, while nearly half said they wanted such services.
Two new studies published in Annals of Internal Medicine found that younger women at increased risk for breast cancer may benefit from biennial mammography screening beginning at age 40. The data suggest that this approach has more benefits than harms for women with a two-fold increased risk. Meanwhile, hospital management strategies h...
A new analysis suggests that every-other-year mammography screening offers a better balance of benefits and harms for women aged 40 to 49 with an increased risk of developing breast cancer. Digital mammography screening resulted in greater false-positive results and harm compared to film mammography.
Researchers found that automated breast volume sonography (ABVS) detected suspicious lesions and uncovered additional cases compared to hand-held ultrasound. ABVS helped identify new breast cancers in mammographically negative cases, improving breast cancer detection rates.
A Moffitt researcher has received a $100,000 grant from General Electric to develop a genetic tool that can identify an individual's predisposition to developing or resisting breast cancer metastasis. The study aims to evaluate inherited changes in DNA predictive of and identify risk for developing or resisting breast cancer metastasis.
A new study found that only 6% of breast cancer survivors experience persistent and debilitating fatigue a year after treatment, contradicting previous reports. The researchers suggest that factors unrelated to the cancer or its treatment may have contributed to the high rates of reported fatigue.
A study published in American Journal of Roentgenology found that routine screening mammography benefits women between 40-49 years by detecting smaller tumors and high-risk lesions at earlier stages. This practice can lead to improved survival rates and reduced need for chemotherapy or extensive surgery.
Researchers at the University of Illinois Chicago are developing a community-based weight loss program for African American breast cancer survivors. The program aims to improve diet and physical activity habits, as well as reduce body mass index and weight-related health risks.
The study found that overactivation of RANK signalling pathway promotes tumour stem cells, increasing tumour growth and metastasis in human breast epithelial cells. High levels of RANK protein are associated with poor prognosis tumours and basal type tumours.
A study by Concordia University found that breast cancer survivors who can redefined their goals show an overall improvement in well-being. The researchers measured the capacity to adjust goals and found a positive association with more physical activity, emotional well-being, and fewer physical symptoms.